Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Vagus Nerve Stimulation for Refractory Seizures in Children with Hypoxic Brain Damage

Introduction to VNS Therapy

  • The FDA approved VNS in 1997 specifically for patients with refractory epilepsy who have failed to control seizures with antiepileptic medications alone, typically after trying two or more anti-epileptic drugs 1
  • The American Academy of Neurology confirms this indication for patients with refractory epilepsy who have failed pharmacologic solutions 2, 1

Efficacy and Safety of VNS

  • Approximately 51% of patients experience ≥50% reduction in seizure frequency with VNS 1
  • Continuous intermittent stimulation provides preventive seizure control 1
  • Closed-loop stimulation triggered by ictal tachycardia can abort seizures early, reducing seizure duration from ~30 seconds to ~5 seconds when delivered within 3 seconds of onset 3, 4

Optimization and Clinical Decision-Making

  • For non-responders to initial settings, increasing the duty cycle can significantly improve outcomes, with responder rates increasing from 19% to 35% (p = 0.046) 1
  • Confirm refractory epilepsy: Patient has failed ≥2 antiepileptic drugs 2, 1

REFERENCES

1

Vagus Nerve Stimulation in Refractory Epilepsy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Vagal Nerve Stimulator for Post-Stroke Hemiparesis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025